Drugs / 131 I-Metaiodobenzylguanidine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT01850888 | Dec 2013 → Oct 2025 | neuroblastoma, pheochromocytoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03649438 | — | neuroblastoma, pheochromocytoma | University of Texas Southwestern Medical Center | No longer available | No outcome recorded |
| — | NCT03015844 | — | neuroblastoma, pheochromocytoma | Northwell Health | Available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131 I-Metaiodobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01850888 ↗ |
| Route | Intravenous | “will be infused intravenously over 90-120 minutes” NCT01850888 ↗ |